Looking to the future, and hoping that current downward trends in malaria are sustained, we need to evaluate the newly introduced antimalarials (piperaquine and pyronaridine look promising12) as well as mefloquine to assess whether and when is the best time to give IPT.
Intermittent preventive treatment (IPT) is a promising strategy for previous termmalarianext term control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa.
The RTS,S/AS01E malaria vaccine candidate has recently entered phase 3 testing. Reaching this important milestone is the culmination of more than 20 years of research and development by GlaxoSmithKline and partners and collaborators. The vaccine has been developed to protect young children and infants living in sub-Saharan Africa against clinical and severe disease caused by Plasmodium falciparum infection.